Cellectis: Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis, a clinical-stage biopharmaceutical company, is pioneering allogeneic CAR-T immunotherapies using its TALEN^® gene editing technology. As of January 31, 2021, the company has a total of 43,029,305 shares and 49,093,894 voting rights. Cellectis focuses on developing UCART product candidates to treat unmet medical needs in various cancers including acute myeloid leukemia and multiple myeloma. The company operates in Paris, New York, and Raleigh, and is listed on both Nasdaq (CLLS) and Euronext Growth (ALCLS).

Positive

• Development of innovative CAR-T therapies targeting unmet needs in oncology.
• Significant expertise in gene editing with over 21 years in the industry.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
01/31/2021	43,029,305	49,093,894

About Cellectis
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN^®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN^® is a registered trademark owned by Cellectis.

For further information, please contact:

Media contacts:
Jennifer Moore, SVP, Public Relations & NY Site Head 917-580-1088, media@cellectis.com
IR contact:
Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com

PDF available at: http://ml.globenewswire.com/Resource/Download/b0bfbf12-944e-41fa-846f-2df5a4b5900d 

FAQ

What is the latest share information for Cellectis (CLLS)?

As of January 31, 2021, Cellectis has 43,029,305 shares and 49,093,894 voting rights.

What is Cellectis focused on developing?

Cellectis is focused on developing UCART product candidates for treating various cancers, including AML and multiple myeloma.

Where is Cellectis headquartered?

Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, North Carolina.

On which exchanges is Cellectis listed?

Cellectis is listed on Nasdaq under ticker CLLS and on Euronext Growth under ticker ALCLS.